Advertisement


Julie Côté, MD, on Multiple Myeloma: Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients

2022 ASH Annual Meeting and Exposition

Advertisement

Julie Côté, MD, of CHU de Québec–Université Laval, discusses findings from the Canadian Myeloma Research Group database, which showed that integrating bortezomib and lenalidomide into the autologous stem cell transplant (ASCT) sequence produces a median overall survival rate ≥ 10 years in most patients with newly diagnosed multiple myeloma. These observations highlight the contribution of post-ASCT maintenance, particularly lenalidomide given until disease progression, when used in multiple patient groups including those with and without high risk, as well as those requiring a second induction regimen (Abstract 117).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The standard of care for multiple myeloma patients with a new diagnosis and for patients that are transplant eligible in Canada, is to first to start with a bortezomib-based induction and then go with a high dose melphalan, an autologous stem cell transplant, followed by lenalidomide maintenance until progression. So, the aim of our study was really to look at the outcomes in details of this patient population in Canada, in the real world setting. So, using our national myeloma database from the C M R G, known as the Canadian Myeloma Research Group, all the patients who received an autologous stem cell transplant for multiple myeloma in the first line setting, from January 2007 to December 2021, were included. So, this gives us 3,800 patients approximately, and most of them received a bortezomib-based induction, mostly being CYBORD, in 72%. We had mostly single-transplant patients. Only 8% received tandem transplant, and it was mostly in high risk patients. 18% of the population were high risk. And what's interesting to see is that, overall with one single transplant, median PFS was around 35 months, and median overall survival was around 10 years. And median overall survival was around 10 years for approximately all subgroup patients, except in high-risk patients; so high-risk patients had inferior outcomes. For consolidation therapy, it's not root routinely available in Canada, so only a few patients received that kind of therapy, about 5%. It was mostly a regimen combining a ubiquitin and a proteasome inhibitor. Globally, consolidation leads to a better PFS, but with no significant gain on OS. For maintenance therapy, about half of our court received maintenance therapy, and it was mostly lenalidomide-based regimen. Maintenance therapy was leading to a significant benefit on PFS and OS, in all risk subgroups, although it does not completely abrogate the negative impact of high risk cytogenetics in the high risk patients. Globally, with the lenalidomide-based maintenance regimen, the PFS was around 4.5 years, and the overall survival around 13 years. As you can see, this real world data covers about 15 years in our court of timeline. And it really shows that the integration of bortezomib and lenalidomide in the transplant sequence, leads to an overall survival of about 10 years in most autologous stem cell transplant patient. It also highlights the beneficial contribution of lenalidomide mainstream therapy in patients without and with high risks, and also in patients receiving a second course of induction. Indeed, these patients had significantly inferior outcomes compared to those receiving only one induction regimen, but with maintenance therapy, outcomes would were comparable even though you received one or two induction regimen. So, this really highlights the importance of maintenance therapy in these subgroups. Right now, further analysis are ongoing, to look at relationship between treatment outcomes, patients characteristics, and these results will really serve as Canadian benchmarks to compare with newer approaches that are eventually coming.

Related Videos

Leukemia

Anand P. Jillella, MD, on Acute Promyelocytic Leukemia: A Simplified Patient Care Strategy to Decrease Early Deaths

Anand P. Jillella, MD, of Georgia Cancer Center at Augusta University, discusses results from the ECOG-ACRIN EA9131 Trial, which showed that using a simplified treatment algorithm and management recommendations made by a group of specialists, resulted in a dramatic improvement in 1-year survival of patients with acute promyelocytic leukemia (Abstract 421).

Lymphoma
Genomics/Genetics

Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD: New Findings on How the IRF4 Gene Shapes Tumor Immunity in Follicular Lymphoma

Stephen M. Ansell, MD, PhD, and Patrizia Mondello, MD, PhD, both of the Mayo Clinic, discuss the 20% of patients with follicular lymphoma (FL) who relapse early and experience a poor prognosis. The researchers found that FLs with high levels of IRF4 expression are associated with a suppressive tumor microenvironment, and selective IRF4 silencing restores antilymphoma T-cell immunity. Further investigation is warranted to identify the mechanisms by which IRF4 controls tumor immunity to develop precision therapies for this population (Abstract 70).

Leukemia
Genomics/Genetics

Irene Roberts, MD, on Leukemogenesis in Infants With Trisomy 21

Irene Roberts, MD, of Oxford’s Weatherall Institute of Molecular Medicine, discusses children with Down syndrome, who have a more than 100-fold increased risk of developing acute myeloid leukemia before their fourth birthday compared to children without Down syndrome. Their risk of acute lymphoblastic leukemia is also increased by around 30-fold. Dr. Roberts details current knowledge about the biologic and molecular basis of this relationship between leukemia and Down syndrome, the role of trisomy 21 in leukemogenesis, and the clinical implications of these findings.

Leukemia
Lymphoma

Jennifer R. Brown, MD, PhD, on CLL/SLL: New Findings on Zanubrutinib vs Ibrutinib for Relapsed or Refractory Disease

Jennifer R. Brown, MD, PhD, of Dana-Farber Cancer Institute, discusses phase III findings of the ALPINE study, which showed that zanubrutinib is more efficacious and better tolerated than ibrutinib as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). In this first head-to-head comparison of the two BTK inhibitors, the superior progression-free survival of zanubrutinib was observed across all major subgroups, including high-risk patients (Abstract LBA-6).

Leukemia

Mark R. Litzow, MD, on ALL: Consolidation Therapy With Blinatumomab Improves Overall Survival

Mark R. Litzow, MD, of the Mayo Clinic, discusses phase III results from the ECOG-ACRIN E1910 Trial, which show that adding blinatumomab to consolidation chemotherapy resulted in a significantly better overall survival in adult patients aged 30 to 70 years with newly diagnosed B-lineage acute lymphocytic leukemia (ALL) who were measurable residual disease–negative after receiving intensification chemotherapy. The authors believe this may represent a new standard of care for this population (Abstract LBA-1).

Advertisement

Advertisement




Advertisement